Melanoma clinical trials

Explore recruiting melanoma clinical trials.

Recruiting melanoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma – NADINA

Netherlands, Italy, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melanoma

Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

Finland, Norway, Denmark, France, Italy, Austria +3 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma

Germany, Lithuania, Spain, Estonia, Italy, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, Open-Label, Multicenter, Non-Randomized Study Of The Efficacy And‬ Safety Of Enfortumab Vedotin In Combination With Pembrolizumab Previously Treated‬ Advanced Melanoma‬

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized Controlled Phase II Clinical Trial with Intradermal IMO-2125 (Tilsotolimod) in clinical cT3-4N0M0 Melanoma (Intrim 1 study)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Melanoma trials by city

Melanoma in Toronto Melanoma in Vancouver Melanoma in Montreal Melanoma in Calgary Melanoma in Edmonton Melanoma in Ottawa Melanoma in Winnipeg Melanoma in Quebec City Melanoma in Hamilton Melanoma in Kitchener Melanoma in London Melanoma in Halifax Melanoma in New York Melanoma in Los Angeles Melanoma in Chicago Melanoma in Houston

Other conditions

Uterine fibroids Menopause Infertility Erectile dysfunction Enlarged prostate (BPH) Breast cancer Prostate cancer Lung cancer Non-small cell lung cancer Colorectal cancer Pancreatic cancer Ovarian cancer Leukemia Lymphoma Multiple myeloma Bladder cancer Kidney cancer Liver cancer Glioblastoma Head and neck cancer Cervical cancer Endometrial cancer Gastric cancer Age-related macular degeneration